EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 7, 2015, Pages 727-754

  Boyman, O ^a   Kaegi, C ^a   Akdis, M ^b,c   Bavbek, S ^d   Bossios, A ^e   Chatzipetrou, A ^f   Eiwegger, T ^g   Firinu, D ^h   Harr, T ⁱ   Knol, E ^j   Matucci, A ^k   Palomares, O ^l   Schmidt Weber, C ^m   Simon, H U ⁿ   Steiner, U C ^o   Vultaggio, A ^k   Akdis, C A ^b,c   Spertini, F ^p  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CHRISTINE KÜHNE CENTER FOR ALLERGY RESEARCH AND EDUCATION CK CARE   (Switzerland)

^d ANKARA UNIVERSITY   (Turkey)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF CAGLIARI   (Italy)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k CAREGGI UNIVERSITY HOSPITAL   (Italy)

^l UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^m INSTITUTE OF EPIDEMIOLOGY   (Germany)

ⁿ UNIVERSITY OF BERN   (Switzerland)

^o Inst of Immunology and Allergology   (Switzerland)

^p LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

allergic rhinitis; asthma; atopic dermatitis; eosinophilic disorders; food allergy; hymenoptera allergy; urticaria

Indexed keywords

ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ALTRAKINCEPT; ANRUKINZUMAB; BENRALIZUMAB; BIOLOGICAL PRODUCT; BRODALUMAB; CANAKINUMAB; DACLIZUMAB; DUPILUMAB; EFALIZUMAB; ENOKIZUMAB; FEZAKINUMAB; LEBRIKIZUMAB; LIGELIZUMAB; MEPOLIZUMAB; MOGAMULIZUMAB; OMALIZUMAB; PASCOLIZUMAB; PITRAKINRA; QUILIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESLIZUMAB; RILONACEPT; RITUXIMAB; SECUKINUMAB; TRALOKINUMAB; UNINDEXED DRUG; USTEKINUMAB; ANTIALLERGIC AGENT; ANTIGEN; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CLINICAL IMMUNOLOGY; DRUG SAFETY; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GRANULOMA; FOOD ALLERGY; HUMAN; HYMENOPTERA; HYPEREOSINOPHILIC SYNDROME; IMMUNOTHERAPY; NOSE POLYP; PRIORITY JOURNAL; REVIEW; URTICARIA; CLINICAL TRIAL (TOPIC); HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; TREATMENT OUTCOME;

ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS; BIOLOGICAL FACTORS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; TREATMENT OUTCOME;

EID: 84931569794     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12616     Document Type: Review

References (205)

1. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al., Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127: 355-360.
2. Holgate ST,. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-683.
3. Akdis CA,. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 2012; 18: 736-749.
4. Holgate S, Smith N, Massanari M, Jimenez P,. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64: 1728-1736.
5. Paul WE, Zhu J,. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10: 225-235.
6. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, et al., Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 2014; 6: 243ra285.
7. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S,. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114: 527-530.
8. Townsend MJ, Monroe JG, Chan AC,. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010; 237: 264-283.
9. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al., Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
10. Antohe I, Croitoru R, Antoniu S,. Tralokinumab for uncontrolled asthma. Expert Opin Biol Ther 2013; 13: 323-326.
11. Beadling C, Slifka MK,. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz) 2006; 54: 15-24.
12. Gaffen SL,. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-567.
13. Beck A, Reichert JM,. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4: 419-425.
14. A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 761 in subjects with asthma. http://clinicaltrials.gov/ct2/show/study/NCT01514981: Amgen.
15. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al., Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008; 178: 1002-1008.
16. Wathion N,. Public statement on zenapex (daclizumab): withdrawal of the marketing authorisation in the European Union. http://www.ema.europa.eu/docs/en-GB/document-library/Public
17. A phase 1, randomized, placebo-controlled, dose-escalation study to evaluate the safety of MEDI4212 in allergic subjects. http://clinicaltrials.gov/ct2/show/study/NCT01544348. MedImmune LLC.
18. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al., Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154: 573-582.
19. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al., Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-1015.
20. Hoshino M, Ohtawa J,. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012; 83: 520-528.
21. Kopp MV,. Omalizumab: anti-IgE therapy in allergy. Curr Allergy Asthma Rep 2011; 11: 101-106.
22. Rabe KF, Calhoun WJ, Smith N, Jimenez P,. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011; 66: 1142-1151.
23. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al., Italian real-life experience of omalizumab. Respir Med 2010; 104: 1410-1416.
24. McKeage K,. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs 2013; 73: 1197-1212.
25. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al., Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131: 110-116.
26. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al., Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
27. Campbell JD, Spackman DE, Sullivan SD,. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010; 65: 1141-1148.
28. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al., Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125: 383-389.
29. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U,. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010; 21: e160-e165.
30. Casale TB, Stokes JR,. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127: 8-15.
31. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al., Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117: 134-140.
32. A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity following subcutaneous injections of QGE031 in Japanese atopic male subjects. http://clinicaltrials.gov/ct2/show/NCT01596712: Novartis Pharmaceuticals.
33. A randomized, double-blind, placebo- and comparator-controlled study evaluating the effect of multiple doses of QGE031 compared to Omalizumab in asthma induced by allergen bronchial provocation. http://clinicaltrials.gov/ct2/show/study/NCT01703312: Novartis Pharmaceuticals.
34. An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240 mg QGE031 given every 4 Weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201. http://clinicaltrials.gov/ct2/show/NCT02075008: Novartis Pharmaceuticals.
35. A multi-center, randomized, double-blind, placebo and active-controlled study with exploratory DR to investigate the efficacy and safety of 16 wks treatment with s.c. QGE031 in asthma patients not adequately controlled with high-dose inhaled corticosteroids and long acting ß2-agonists. http://clinicaltrials.gov/ct2/show/study/NCT01716754: Novartis Pharmaceuticals.
36. A phase IIb, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and dosing regimens of MEMP1972A in adults with allergic asthma who are inadequately controlled on inhaled corticosteroids and a second controller (COSTA). http://clinicaltrial.gov/ct2/show/study/NCT01582503: Genentech.
37. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, et al., Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 1816-1823.
38. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et al., Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963-970.
39. Girodet PO, Ozier A, Bara I, Tunon de Lara JM, Marthan R, Berger P,. Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. Pharmacol Ther 2011; 130: 325-337.
40. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, et al., Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res 2011; 28: 2530-2542.
41. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al., A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788-796.
42. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al., Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466.
43. Pelaia G, Vatrella A, Maselli R,. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012; 11: 958-972.
44. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M,. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-1431.
45. Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, et al., IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012; 130: 516-522.
46. A randomized, double-blind, placebo controlled study to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to moderate asthma. http://clinicaltrials.gov/ct2/show/study/NCT01568762: Novartis Pharmaceuticals.
47. A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists. http://clinicaltrials.gov/ct2/show/study/NCT01479595: Novartis Pharmaceuticals.
48. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al., Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125: 1237-1244.
49. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al., Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086-1096.
50. Ghazi A, Trikha A, Calhoun WJ,. Benralizumab-a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma. Expert Opin Biol Ther 2012; 12: 113-118.
51. Busse WW,. A multicentre, randomized, double-blind, parallel group, placebo-controlled, phase III efficacy and safety study of benralizumab (MEDI-563) added to medium-dose inhaled corticosteroid plus long-acting ß2 agonist in patients with uncontrolled asthma. http://www.clinicaltrials.gov/ct2/show/study/NCT01947946: AstraZeneca.
52. Fitzgerald M,. A multicentre, randomized, double-blind, parallel group, placebocontrolled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting ß2 agonist (CALIMA). http://www.clinicaltrials.gov/ct2/show/NCT01914757: AstraZeneca.
53. Bleecker ER,. A multicentre, randomized, double-blind, parallel group, placebo-controlled, phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting ß2 agonist in patients with uncontrolled asthma. www.clinicaltrials.gov/show/NCT01928771: AstraZeneca.
54. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al., A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-1071.
55. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al., Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
56. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al., Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
57. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
58. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al., Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
59. Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, et al., Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 2012; 130: 563-571.
60. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al., Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011; 11: 14.
61. White B, Leon F, White W, Robbie G,. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther 2009; 31: 728-740.
62. Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA,. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 2013; 14: 93.
63. Assessment of the safety of ABT-308 in healthy volunteers and subjects with asthma. http://clinicaltrials.gov/ct2/show/NCT00986037: Abbott.
64. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, et al., Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183: 1007-1014.
65. van Hartingsveldt B, Nnane IP, Bouman-Thio E, Loza MJ, Piantone A, Davis HM, et al., Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol 2013; 75: 1289-1298.
66. Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, et al., A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol 2013; 75: 118-128.
67. De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, et al., Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014; 133: 989-996.
68. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al., A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330-338.
69. Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, et al., Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013; 132: 567-574.
70. A randomized, double blind, placebo controlled, study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics Of multiple doses of intravenous administration of QAX576 in controlled or partially controlled asthma patients. http://clinicaltrials.gov/ct2/show/study/NCT00940160: Novartis Pharmaceuticals.
71. A multi-center, randomized, double blind, placebo-controlled, 'add-on' study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (=18-75 years) with persistent asthma not adequately controlled with inhaled corticosteroids and long acting ß2-agonists. http://clinicaltrials.gov/ct2/show/study/NCT01130064: Novartis Pharmaceuticals.
72. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al., Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294-1302.
73. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al., Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-1189.
74. A randomized, double-blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroids and long acting beta-agonists. http://clinicaltrials.gov/ct2/show/study/NCT01478360: Novartis Pharmaceuticals.
75. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al., Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1705-1713.
76. Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, et al., OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 2014; 44: 29-37.
77. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al., Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018.
78. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al., Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697-708.
79. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST,. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63: 584-591.
80. Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, et al., Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011; 37: 1352-1359.
81. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, et al., A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-558.
82. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al., The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174: 753-762.
83. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al., Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102-2110.
84. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al., Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286: 2956-2967.
85. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al., Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-259.
86. Okubo K, Ogino S, Nagakura T, Ishikawa T,. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006; 55: 379-386.
87. Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T,. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 2009; 149: 239-245.
88. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al., Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120: 688-695.
89. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al., Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39: 271-279.
90. Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, et al., Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013; 24: 427-433.
91. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al., Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-280.
92. Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment of seasonal allergic rhinitis. http://clinicaltrials.gov/show/NCT01018693: Novartis Pharmaceuticals.
93. A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to timothy grass pollen. http://clinicaltrials.gov/ct2/show/study/NCT00584584: Novartis.
94. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al., A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127: 1309-1310.
95. Kulis MD, Guo R, Vickery BP, Steele HP, Kim E, Burks AW,. Length of avoidance period following peanut oral immunotherapy influences effector cell suppression and clinical outcomes. J Allergy Clin Immunol 2014; 133: AB153.
96. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT,. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011; 127: 1622-1624.
97. Nowak-Wegrzyn A, Sampson HA,. Future therapies for food allergies. J Allergy Clin Immunol 2011; 127: 558-573.
98. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al., Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131: 1288-1296.
99. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, et al., Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol 2012; 5: 267-276.
100. Khoriaty E, Umetsu DT,. Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res 2013; 5: 3-15.
101. Schulze J, Rose M, Zielen S,. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62: 963-964.
102. Kontou-Fili K,. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63: 376-378.
103. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P,. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19: 225-229.
104. Kontou-Fili K, Filis CI,. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009; 64: 1384-1385.
105. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E,. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 2008; 18: 225-226.
106. Arkwright PD,. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol 2009; 123: 510-511.
107. Mallipeddi R, Grattan CE,. Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol 2007; 32: 333-334.
108. Chakravarty SD, Yee AF, Paget SA,. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol 2011; 128: 1354-1355.
109. Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, et al., Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-935.
110. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al., Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101-109.
111. Metz M, Ohanyan T, Church MK, Maurer M,. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73: 57-62.
112. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P,. Omalizumab-an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66: 303-305.
113. Song CH, Stern S, Giruparajah M, Berlin N, Sussman GL,. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2013; 110: 113-117.
114. Metz M, Bergmann P, Zuberbier T, Maurer M,. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 247-249.
115. Boyce JA,. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117: 1415-1418.
116. Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M,. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 1563-1565.
117. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al., Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154: 177-180.
118. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK,. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-573.
119. Maurer M, Magerl M, Metz M, Zuberbier T,. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013; 11: 971-978.
120. A study of quilizumab versus placebo in patients with refractory chronic spontaneous urticaria. http://clinicaltrials.gov/ct2/show/NCT01987947: Genentech.
121. Hoffman HM,. Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 2009; 124: 1129-1138.
122. Caorsi R, Federici S, Gattorno M,. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012; 12: 81-86.
123. Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, et al., Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68: 562-568.
124. Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, et al., Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67: 943-950.
125. de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A,. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann Rheum Dis 2013; 72: 1634-1638.
126. Krause K, Mahamed A, Weller K, Metz M, Zuberbier T, Maurer M,. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J Allergy Clin Immunol 2013; 132: 751-754.
127. Sand FL, Thomsen SF,. TNF-alpha inhibitors for chronic urticaria: experience in 20 patients. J Allergy 2013; 2013: 130905.
128. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL,. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol 2011; 64: 1221-1222.
129. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M,. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007; 119: 752-754.
130. Gualdi G, Monari P, Rossi MT, Crotti S, Calzavara-Pinton PG,. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. Br J Dermatol 2012; 166: 1373-1374.
131. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N,. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008; 122: 423-424.
132. Moul DK, Routhouska SB, Robinson MR, Korman NJ,. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008; 58: 984-989.
133. Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T,. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010; 24: 837-839.
134. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, et al., Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007; 56: 222-227.
135. Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S,. Efalizumab. Expert Opin Drug Saf 2011; 10: 239-251.
136. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU,. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121: 122-128.
137. Sediva A, Kayserova J, Vernerova E, Polouckova A, Capkova S, Spisek R, et al., Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121: 1515-1516.
138. Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME, Paravisini A, Zubeldia-Ortuno JM, Gil-Herrera J, et al., Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013; 23: 190-196.
139. Guttman-Yassky E, Dhingra N, Leung DY,. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013; 13: 549-561.
140. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G,. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010; 8: 990-998.
141. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, et al., Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225.
142. A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with moderate to severe atopic dermatitis. http://clinicaltrials.gov/ct2/show/study/NCT01552629: Novartis Pharmaceuticals.
143. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al., Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139.
144. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al., Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693-696.
145. Oldhoff JM, Darsow U, Werfel T, Bihari IC, Katzer K, Laifaoui J, et al., No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006; 141: 290-294.
146. Agusti-Mejias A, Messeguer F, Garcia R, Febrer I,. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 2013; 25: 368-370.
147. Puya R, Alvarez-Lopez M, Velez A, Casas Asuncion E, Moreno JC,. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 2012; 51: 115-116.
148. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study of ustekinumab in adult Japanese subjects with severe atopic dermatitis. In NCT01945086. http://clinicaltrials.gov/ct2/show/NCT01945086: Janssen Pharmaceutical K.K.
149. A randomized placebo-controlled study to determine the safety, tolerability, pharmacodynamics and clinical efficacy of ILV-094 (an IL-22 antibody) administered intravenously to subjects with atopic dermatitis (AD). http://clinicaltrials.gov/ct2/show/NCT01941537: Rockefeller University.
150. A two-part, phase 1, single-dose study of IL-31 mAb (anti-interleukin 31 monoclonal antibody); in healthy subjects and adults with atopic dermatitis. http://clinicaltrials.gov/ct2/show/NCT01614756: Bristol-Myers Squibb.
151. A phase 2 study of CIM331 for atopic dermatitis patients. http://clinicaltrials.gov/ct2/show/NCT01986933: Chugai Pharmaceutical.
152. Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S,. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005; 53: 358-359.
153. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M,. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52: 522-526.
154. A randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 157 in healthy subjects and subjects with moderate to severe atopic dermatitis. http://clinicaltrials.gov/ct2/show/study/NCT00757042: Amgen.
155. Zirbes JM, Milla CE,. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43: 607-610.
156. Elmallah MK, Hendeles L, Hamilton RG, Capen C, Schuler PM,. Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab). J Pediatr Pharmacol Ther 2012; 17: 88-92.
157. Wong R, Wong M, Robinson PD, Fitzgerald DA,. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Paediatr Respir Rev 2013; 14: 22-24.
158. Tanou K, Zintzaras E, Kaditis AG,. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49: 503-507.
159. Brinkmann F, Schwerk N, Hansen G, Ballmann M,. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010; 65: 134-135.
160. Jat KR, Walia DK, Khairwa A,. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2013; 9: CD010288.
161. Perez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O, et al., Effects of omalizumab in Aspergillus-associated airway disease. Thorax 2011; 66: 539-540.
162. Tillie-Leblond I, Germaud P, Leroyer C, Tetu L, Girard F, Devouassoux G, et al., Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011; 66: 1254-1256.
163. Collins J, Devos G, Hudes G, Rosenstreich D,. Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 2012; 5: 65-70.
164. Homma T, Kurokawa M, Matsukura S, Yamaguchi M, Adachi M,. Anti-IgE therapy for allergic bronchopulmonary aspergillosis. J Microbiol Immunol Infect 2013. doi: 10.1016/j.jmii.2013.1010.1003.
165. Moss RB,. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J 2014; 43: 1487-1500.
166. Giavina-Bianchi P, Agondi R, Kalil J,. One year administration of anti-IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol 2008; 146: 176.
167. Bargagli E, Madioni C, Olivieri C, Penza F, Rottoli P,. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma 2008; 45: 115-116.
168. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J,. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol 2008; 122: 217-218.
169. Pabst S, Tiyerili V, Grohe C,. Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome. Thorax 2008; 63: 747-748.
170. Iglesias E, Camacho Lovillo M, Delgado Pecellin I, Cruz Lirola MJ, Neyra Falcon MD, Quero Salazar JC, et al., Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 2014; 49: E78-E81.
171. Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al., Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 267-270.
172. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME,. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1336-1343.
173. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B,. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155: 341-343.
174. Penn R, Mikula S,. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007; 21: 428-432.
175. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al., Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128: 989-995.
176. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al., Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006; 118: 1133-1141.
177. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, et al., Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009; 15: 368-373.
178. Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon HU,. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol 2015; 55: 633-656.
179. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S,. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk 2013; 13: 287-291.
180. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al., Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339.
181. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al., Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215-1228.
182. Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, et al., Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013; 131: 461-467.
183. Roufosse F, de Lavareille A, Schandene L, Cogan E, Georgelas A, Wagner L, et al., Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126: 828-835.
184. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB,. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103: 2939-2941.
185. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al., Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006; 118: 1312-1319.
186. Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al., Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010; 59: 21-30.
187. Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al., An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011; 141: 1593-1604.
188. Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, et al., Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 2013; 131: 1576-1582.
189. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP,. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42: 712-737.
190. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, et al., Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012; 129: 456-463.
191. A double blinded randomized placebo-controlled trial of intravenous QAX576 in the treatment of eosinophilic esophagitis (EoE). http://clinicaltrials.gov/ct2/show/study/NCT01022970: Novartis Pharmaceuticals.
192. Boyman O, Comte D, Spertini F,. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10: 612-627.
193. Fanta CH,. Asthma. N Engl J Med 2009; 360: 1002-1014.
194. Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, et al., Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007; 37: 197-207.
195. Cox LS,. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol 2009; 5: 4.
196. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al., Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-1012.
197. Salliot C, Dougados M, Gossec L,. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
198. Busse WW, Ring J, Huss-Marp J, Kahn JE,. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010; 125: 803-813.
199. Liu Y, Zhang S, Li DW, Jiang SJ,. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One 2013; 8: e59872.
200. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al., Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from five years of follow-up. Br J Dermatol 2013; 168: 844-854.
201. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, et al., Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66: 731-741.
202. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al., Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402-411.
203. Furst DE,. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-346.
204. Documed. Compendium.ch: Das Arzneimittelkompendium der Schweiz, 2015.
205. Gleich GJ, Klion AD, Lee JJ, Weller PF,. The consequences of not having eosinophils. Allergy 2013; 68: 829-835.